Patient Safety Risk
The Food and Drug Administration Feb. 23 withdrew approval of Pepaxto (melphalan flufenamide), a drug once used with dexamethasone to treat certain U.S. patients with multiple myeloma, because a post-approval trial did not show it safe or effective.
In this podcast episode, listeners will learn how to create a culture of cybersecurity in their organization and facilitate board-level risk visibility and accountability to ultimately protect patient safety.
AHA submitted comments on how the Agency for Healthcare Research and Quality can best support the field in advancing patient safety through an action alliance, which the agency is launching in partnership with health care systems and patient safety advocates
Abbott has recalled certain Dragonfly OpStar imaging catheters because a marker band may remain in the patient after use.
AHA today urged the FTC to scrutinize commercial health plans that steer patients to third-party specialty pharmacies in which they have a financial interest.
FDA issues updates on a COVID-19 monoclonal antibody and antiviral pill, and certain Fresenius Medical Care hemodialysis machines.
Medtronic this week alerted health care providers to a defect in its Heartware Ventricular Assist Device System that may cause the internal pump to malfunction.
DEA offers posters and other materials to help hospitals and other partners promote the event in their community.
The agency has received reports describing serious adverse events and deaths after ventilation failure using silicone-based electromyogram endotracheal tubes.
The agency recommends health care facilities that still use fixed endcap duodenoscopes complete their transition to newer models that can lower infection risks.